Terms ending in 2039
Teva Pharmaceutical Industries, Ltd.
Every in-force patent on Teva Pharmaceutical Industries, Ltd.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,752,095 | Medroxyprogesterone Acetate Injectable Compositions and Methods of Use In force · High confidence | Family Health International D/B/A Fhi 360 | In force | High confidence | |
| US 11,642,451 | Medical Injection Device Packaging In force · High confidence | Teva Pharmaceutical Industries Ltd. | In force | High confidence |
2 of 2 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Teva Pharmaceutical Industries, Ltd..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.